223 related articles for article (PubMed ID: 21908031)
1. Effect of rituximab on human in vivo antibody immune responses.
Pescovitz MD; Torgerson TR; Ochs HD; Ocheltree E; McGee P; Krause-Steinrauf H; Lachin JM; Canniff J; Greenbaum C; Herold KC; Skyler JS; Weinberg A;
J Allergy Clin Immunol; 2011 Dec; 128(6):1295-1302.e5. PubMed ID: 21908031
[TBL] [Abstract][Full Text] [Related]
2. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
[TBL] [Abstract][Full Text] [Related]
3. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174.
Bearden CM; Agarwal A; Book BK; Vieira CA; Sidner RA; Ochs HD; Young M; Pescovitz MD
Am J Transplant; 2005 Jan; 5(1):50-7. PubMed ID: 15636611
[TBL] [Abstract][Full Text] [Related]
4. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Pescovitz MD; Greenbaum CJ; Krause-Steinrauf H; Becker DJ; Gitelman SE; Goland R; Gottlieb PA; Marks JB; McGee PF; Moran AM; Raskin P; Rodriguez H; Schatz DA; Wherrett D; Wilson DM; Lachin JM; Skyler JS;
N Engl J Med; 2009 Nov; 361(22):2143-52. PubMed ID: 19940299
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous assessment of rotavirus-specific memory B cells and serological memory after B cell depletion therapy with rituximab.
Herrera D; Rojas OL; Duarte-Rey C; Mantilla RD; Angel J; Franco MA
PLoS One; 2014; 9(5):e97087. PubMed ID: 24819618
[TBL] [Abstract][Full Text] [Related]
6. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.
Vallerskog T; Gunnarsson I; Widhe M; Risselada A; Klareskog L; van Vollenhoven R; Malmström V; Trollmo C
Clin Immunol; 2007 Jan; 122(1):62-74. PubMed ID: 17046329
[TBL] [Abstract][Full Text] [Related]
7. Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.
Lunde S; Kristoffersen EK; Sapkota D; Risa K; Dahl O; Bruland O; Mella O; Fluge Ø
PLoS One; 2016; 11(8):e0161226. PubMed ID: 27536947
[TBL] [Abstract][Full Text] [Related]
8. Antibody titers and immune response to diphtheria-tetanus-pertussis and measles-mumps-rubella vaccination in children treated for acute lymphoblastic leukemia.
Ercan TE; Soycan LY; Apak H; Celkan T; Ozkan A; Akdenizli E; Kasapçopur O; Yildiz I
J Pediatr Hematol Oncol; 2005 May; 27(5):273-7. PubMed ID: 15891564
[TBL] [Abstract][Full Text] [Related]
9. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes.
Herold KC; Pescovitz MD; McGee P; Krause-Steinrauf H; Spain LM; Bourcier K; Asare A; Liu Z; Lachin JM; Dosch HM;
J Immunol; 2011 Aug; 187(4):1998-2005. PubMed ID: 21775681
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune response after post-chemotherapy booster diphtheria-tetanus-pertussis vaccine in pediatric oncology patients.
Cheng FW; Leung TF; Chan PK; Lee V; Shing MK; Chik KW; Yuen PM; Li CK
Pediatr Blood Cancer; 2009 Feb; 52(2):248-53. PubMed ID: 18937325
[TBL] [Abstract][Full Text] [Related]
11. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study.
Fluge Ø; Bruland O; Risa K; Storstein A; Kristoffersen EK; Sapkota D; Næss H; Dahl O; Nyland H; Mella O
PLoS One; 2011; 6(10):e26358. PubMed ID: 22039471
[TBL] [Abstract][Full Text] [Related]
12. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study.
Krueger JG; Ochs HD; Patel P; Gilkerson E; Guttman-Yassky E; Dummer W
J Invest Dermatol; 2008 Nov; 128(11):2615-2624. PubMed ID: 18496564
[TBL] [Abstract][Full Text] [Related]
13. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Piccio L; Naismith RT; Trinkaus K; Klein RS; Parks BJ; Lyons JA; Cross AH
Arch Neurol; 2010 Jun; 67(6):707-14. PubMed ID: 20558389
[TBL] [Abstract][Full Text] [Related]
14. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.
Venhoff N; Effelsberg NM; Salzer U; Warnatz K; Peter HH; Lebrecht D; Schlesier M; Voll RE; Thiel J
PLoS One; 2012; 7(5):e37626. PubMed ID: 22629432
[TBL] [Abstract][Full Text] [Related]
15. B-lymphocyte depletion with rituximab and β-cell function: two-year results.
Pescovitz MD; Greenbaum CJ; Bundy B; Becker DJ; Gitelman SE; Goland R; Gottlieb PA; Marks JB; Moran A; Raskin P; Rodriguez H; Schatz DA; Wherrett DK; Wilson DM; Krischer JP; Skyler JS;
Diabetes Care; 2014 Feb; 37(2):453-9. PubMed ID: 24026563
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
Tsuda M; Moritoki Y; Lian ZX; Zhang W; Yoshida K; Wakabayashi K; Yang GX; Nakatani T; Vierling J; Lindor K; Gershwin ME; Bowlus CL
Hepatology; 2012 Feb; 55(2):512-21. PubMed ID: 22006563
[TBL] [Abstract][Full Text] [Related]
17. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.
Kamburova EG; Koenen HJ; Boon L; Hilbrands LB; Joosten I
Am J Transplant; 2012 Feb; 12(2):341-50. PubMed ID: 22070501
[TBL] [Abstract][Full Text] [Related]
18. Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination.
Muller RB; Maier R; Hoschler K; Zambon M; Ludewig B; Herrmann M; Schulze-Koops H; von Kempis J
Clin Exp Rheumatol; 2013; 31(5):723-30. PubMed ID: 23806224
[TBL] [Abstract][Full Text] [Related]
19. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.
Fluge Ø; Risa K; Lunde S; Alme K; Rekeland IG; Sapkota D; Kristoffersen EK; Sørland K; Bruland O; Dahl O; Mella O
PLoS One; 2015; 10(7):e0129898. PubMed ID: 26132314
[TBL] [Abstract][Full Text] [Related]
20. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
Tanaka Y
Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
[No Abstract] [Full Text] [Related]
[Next] [New Search]
